Population Health Research Institute
 | |
| Established | 1992 |
|---|---|
| Research type | Clinical |
Field of research | Epidemiology |
| Director | Salim Yusuf |
| Location | Hamilton, Ontario, Canada |
| L8L 2X2 | |
| Campus | Hamilton General Hospital |
| Affiliations | McMaster University McMaster University Medical School |
The Population Health Research Institute (PHRI), is a population health research institute located at McMaster University Medical School. It was founded in 1992 by Salim Yusuf as a preventative cardiology and therapeutics research program and has emerged as a world leading research institute specializing in epidemiological research, population health and randomized clinical trials.
Research
The PHRI has led multinational trials that have achieved widespread acclaim and influenced medical regulations and approvals around the world. Some of the biggest multinational trials ever published were published at the PHRI including:
- HOPE[1] - Demonstrated the effectiveness of the ACE inhibitor ramipril in secondary prevention of heart disease - NEJM 2000
- INTERHEART[2] - Demonstrated the same 9 risk factors (smoking, lipids, hypertension, diabetes, obesity, diet, physical activity, alcohol consumption, and psychosocial factors) were a significant cause of heart attacks across the world, all ethnic groups and both genders - Lancet 2004
- CURE[3] - Demonstrated that anti-platelet drug clopidogrel with aspirin was superior to placebo with aspirin for patients presenting with NSTEMI - NEJM 2001
- HOPE-3[4] - Demonstrated that rousuvastatin significantly lowered rates of stroke, myocardial infarction and death from cardiovascular causes in intermediate risk patients without cardiovascular disease - NEJM 2016
Researchers
References
- ^ Yusuf, Salim (January 20, 2000). "Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients". NEJM. 342 (3). Retrieved 2 December 2015.
- ^ Yusuf, Salim (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study". Lancet. Retrieved 2 December 2015.
- ^ Yusuf, Salim (August 16, 2001). "EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION". NEJM. 345 (7). Retrieved 2 December 2015.
- ^ Yusuf, Salim (April 2, 2016). "Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease". NEJM. Retrieved 7 April 2016.